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Abstract
The PPARγ nuclear receptor pathway is involved in cancer, but it appears to have both tumor
suppressor and oncogenic functions. In neuroblastoma cells, miR-27b targets the 3′UTR of
PPARγ and inhibits its mRNA and protein expression. miR-27b overexpression or PPARγ
inhibition blocks cell growth in vitro and tumor growth in mouse xenografts. PPARγ activates
expression of the pH regulator NHE1, which is associated with tumor progression. Lastly,
miR-27b through PPARγ regulates NF-κB activity and transcription of inflammatory target genes.
Thus, in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-
promoting function of PPARγ, which triggers an increased inflammatory response. In contrast, in
breast cancer cells, PPARγ inhibits NHE1 expression and the inflammatory response, and it
functions as a tumor suppressor. We suggest that the ability of PPARγ to promote or suppress
tumor formation is linked to cell-type specific differences in regulation of NHE1 and other target
genes.
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INTRODUCTION
Peroxisome proliferators-activated receptors (PPAR) are members of the nuclear receptor
superfamily of ligand-activated transcription factors. Three isoforms, PPARα, PPARβ/δ and
PPARγ, are encoded by three genes that respond to diverse, but distinct, sets of ligands
(Michalik et al., 2004). PPARγ has emerged as an attractive target for cancer therapy due to
its association with many human cancers such as colon, thyroid, breast and prostate
(Michalik et al., 2004). PPARγ is abundant in adipose tissues and is also expressed at a
lower level in skeletal muscles, liver, heart, intestine, vascular smooth muscle, lung, breast,
colon and prostate. Interestingly abundant PPARγ expression has been detected in different
tumors such as transformed human B lymphocyte and myeloid cells lines, astrocytomas
(Chattopadhyay et al., 2000), glioblastoma (Nwankwo & Robbins, 2001; Morosetti et al.,
2004) and neuroblastoma (Han et al., 2001).
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tThe role of PPARγ in tumor development is controversial. It has been suggested that
PPARγ is a tumor suppressor, because ligands that activate PPARγ promote growth
inhibition and apoptosis in cancers of breast (Mueller et al., 1998; Mehta et al., 2000; Kim et
al., 2006), colon (Sarraf et al., 1998), liposarcoma (Tontonoz et al., 1997), and
neuroblastoma (Cellai et al., 2006; Cellai et al., 2010). However, it has been suggested the
anti-tumor effect induced by such PPARγ ligands occurs via a PPARγ-independent
pathway without the presence of the PPARγ receptors (Abe et al., 2002; Lecomte et al.,
2008). Alternatively, several lines of evidence suggest that activated PPARγ is not a tumor
suppressor, but rather functions as an oncogene. First, expression of PPARγ is higher in
human prostate cancer cells than in normal prostate tissues (Han & Roman, 2007). Second,
PPARγ exhibits a pro-tumor effect in mice bearing a mutation in the APC tumor suppressor
gene, because PPARγ agonists increase the frequency and size of colon tumors (Lefebvre et
al., 1998; Saez et al., 1998). Third, PPARγ antagonists have anticancer effects in other cell
lines and mouse models (Cui et al., 2002; Burton et al., 2008).
MicroRNAs play critical roles in many biological processes including cancer by directly
interacting with specific mRNAs through base pairing and then inhibiting expression of the
target genes through a variety of molecular mechanisms (Bartel, 2009; Croce, 2009; Ventura
& Jacks, 2009). The miR-27 family (miR-27a and miR-27b) directly targets PPARγ, and it
inhibits adipocyte differentiation (Karbiener et al., 2009; Kim et al., 2010) and is induced
upon inflammation in macrophages (Jennewein et al., 2010). Here, we show that miR-27b
also targets PPARγ in neuroblastoma cells. miR-27b overexpression or PPARγ inhibition
blocks neuroblastoma growth in vitro and in vivo, and this growth inhibition is associated
with decreased expression of NHE1, a PPARγ target gene, and a reduced inflammatory
response. In contrast, PPARγ inhibits NHE1 expression, the inflammatory response, and
growth of a breast cancer cell line. These results suggest that miR-27b functions as a tumor
suppressor, that PPARγ promotes tumor formation in neuroblastomas, and that cell-type-
specific regulation of NHE1 by PPARγ underlies the difference between the oncogenic and
tumor suppressing functions of PPARγ in different cell types.
RESULTS
miR-27b inhibits PPARγ expression via its 3′UTR in neuroblastoma
As the miR-27 family (miR-27a and miR-27b) directly targets PPARγ in adipocytes and
macrophages (Karbiener et al., 2009; Jennewein et al., 2010; Kim et al., 2010), we examined
whether PPARγ is a direct target of miR-27b in a cancer context. Luciferase reporter
plasmids containing the wild-type (WT) 3′UTR sequence of PPARγ or a deletion mutant
(lacking the 8-bp seed sequence) were transfected into the SK-N-AS neuroblastoma cancer
cell line with miR-27b or an anti-sense RNA against miR-27b (as-miR-27b). PPARγ
luciferase activity of the wild-type reporter is reduced 5-fold upon miR-27b overexpression,
whereas it is increased by 60% upon miR-27b inhibition (Figure 1a). In contrast, no changes
in PPARγ luciferase activity are observed in the mutant reporter plasmid upon
overexpression of miR-27b or as-miR-27b. As expected, antisense-mediated inhibition of
either miR-27a or miR-27b results in increased levels of PPARγ mRNA (Figure 1b). In
addition, PPARγ protein levels are decreased upon overexpression of miR-27b and
increased upon addition of antisense against miR-27b (Figure 1c). Lastly, in 10-day old
tumors generated by injection of SK-N-AS cells in nude mice, PPARγ mRNA expression is
reduced 3-fold in tumors injected intra-tumorally with miR-27b, but not with the control
miRNA (Figure 1d). Thus, miR-27b inhibits PPARγ expression in neuroblastomas cells.
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tmiR-27b inhibits neuroblastoma cell growth in vitro and tumor growth in mouse
xenografts
We investigated the role of miR-27b in neuroblastoma cell growth by overexpressing either
miR-27b or its antisense RNA. Overexpression of miR-27b or miR-27a inhibits cell growth,
whereas overexpression of as-miR-27b or as-miR-27a increases cell growth (Figures 2a).
More importantly, in mouse xenografts involving the neuroblastoma cell line, administration
of four cycles of miR-27b, but not a control miRNA, strongly reduces tumor growth,
whereas tumor growth is enhanced by treatment with as-miR-27b (Figure 2b). These
observations are indicative of a tumor suppressive role for miR-27b in neuroblastomas, and
they are in accord with studies in other types of cancer. Specifically, miR-27b acts as a
tumor suppressor gene in breast cancer, and it is highly expressed in human normal breast
tissues (Lu et al., 2005) but less expressed in breast cancer tissues (Tsuchiya et al., 2006). In
addition, miR-27b expression is suppressed in anaplastic thyroid cancer (Braun et al., 2010).
miR-27b levels are reduced in neuroblastoma tissues
To examine whether the tumor-suppressor effects of miR-27b in neuroblastoma cell lines
are relevant to the human disease, we measured miR-27b RNA levels in tissue samples from
human patients. In all 9 cases tested, miR-27b levels in neuroblastoma tissue were 2–3 fold
lower than in the adjacent non-cancer tissue (Figure 2c). Thus, reduced levels of miR-27b
are associated with neuroblastoma.
PPARγ plays a tumor-promoting role in neuroblastoma
The functional role of PPARγ activation during cancer development remains controversial,
in part because the experiments have been performed with PPARγ agonists or antagonists
that may mediate their effects through non-PPARγ mechanisms (see Introduction). To avoid
this problem, we inhibited expression of the PPARγ gene by an siRNA and found that this
resulted in reduced cell viability (Figure 2a). In accord with these experiments, treatment of
these neuroblastoma cells with the PPARγ antagonist GW9662 inhibits cell growth in vitro
(Figure 2d) and in mouse xenografts (Figure 2e). In addition GW9662 inhibit growth of a
different neuroblastoma cell line (SK-N-SH; Supplementary Figure 1). Lastly, as mentioned
above, miR-27b acts as a tumor suppressor, providing an independent line of evidence that
reduction of PPARγ levels is associated with reduced cancer cell growth. Collectively these
observations strongly suggest that PPARγ has a growth-stimulating and tumor-promoting
role in neuroblastoma cells.
PPARγ activates NHE1 in neuroblastoma cells
Activation of the pH regulator NHE1 causes tumors to become more acidic extracellularly
and more alkaline intracellularly even during the early stages of neoplastic progression, and
hence NHE1 activation is tumor-promoting (Hagag et al., 1987; Ober & Pardee, 1987;
Siczkowski et al., 1994; Reshkin et al., 2000). Indeed, si-RNA-mediated inhibition of NHE1
expression results in reduced growth of SK-N-AS neuroblastoma cells (Figure 2a). NHE1
expression is directly regulated by binding of PPARγ to target sites (PPREs) in the NHE1
promoter, and activated PPARγ inhibits NHE1 expression in breast cancer cell lines (Kumar
et al., 2009; Venkatachalam et al., 2009). These observations are consistent with a number
of studies concluding that PPARγ has anti-tumor effects in breast cancer (Mueller et al.,
1998; Mehta et al., 2000; Girnun et al., 2002; Kim et al., 2006; Kumar et al., 2009).
We independently confirmed the anti-tumor effects of PPARγ in breast cancer cells using
an isogenic model of cellular transformation involving non-transformed mammary epithelial
cells (MCF-10A)(Soule et al., 1990) containing ER-Src, a derivative of the Src kinase
oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (Aziz
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tet al., 1999). Treatment of such cells with tamoxifen rapidly induces Src, and morphological
transformation is observed within 24–36 hours (Hirsch et al., 2009; Iliopoulos et al., 2009),
thereby making it possible to kinetically follow the transition between non-transformed and
transformed cells. In this isogenic model, siRNA-mediated inhibition of PPARγ or
exogenous expression of miR-27b results in increased tumorigenicity (colonies growing in
soft agar; Figure 3a) and invasive growth (MATRIGEL assay; Figure 3b). Furthermore,
tumors derived from these transformed ER-Src cells in mouse xenograft grow more quickly
upon injection of siRNA against PPARγ (Figure 3c). Similar effects of miR-27b on
reducing PPARγ expression (Figure 3d) and increasing invasive growth (Figure 3e) are
observed in two other breast cancer cells lines (MDA-MB-231 and MDA-MB-468).
In contrast to the results in breast cancer cells, several lines of evidence indicate that PPARγ
activates NHE1 expression in neuroblastomas cells. First, expression of as-miR-27b causes
increased NHE1 expression (Figure 4a) along with increased PPARγ expression (Figure 1b,
c) in cell culture. Conversely, expression of miR-27b in mouse xenografts reduces NHE1
(Figure 4b) and PPARγ expression (Figure 1d). Second, treatment of neuroblastoma cells
with siRNA against PPARγ causes a 4-fold decrease in NHE1 expression levels (Figure 4c).
Third, the PPARγ antagonist GW9662 inhibits both PPARγ and NHE1 expression in cell
culture (Figure 4d) and in mouse xenografts (Figure 4e). Taken together, these observations
suggest that PPARγ can activate or inhibit NHE1 expression in a cell-type-specific manner,
and that the differential regulation of NHE1 expression accounts for the opposing tumor-
promoting or tumor-inhibiting effects in these different cell types.
miR-27b and PPARγ regulate the inflammatory response in neuroblastoma cells
The inflammatory transcription factor NF-κB physically interacts with PPARγ (Chung et
al., 2000), and there is a great deal of evidence linking NF-κB and inflammation to cancer
(Balkwill & Mantovani, 2001; Karin, 2006; Naugler & Karin, 2008; Iliopoulos et al., 2009).
We therefore examined the effect of miR-27 and PPARγ on the inflammatory response.
Inhibition of miR-27b in SK-N-AS neuroblastoma cells increases mRNA levels of four
inflammatory factors (IL-1A, JAK2, IL-6 and IL-1B), whereas expression of miR-27b
results in decreased expression (Figure 5a). In addition, mRNA levels of these inflammatory
factors are strongly reduced upon siRNA-mediated (Figure 5a) or pharmacological
inhibition (GW9662) of PPARγ (Figure 5b). Importantly, the increased expression of
inflammatory factors upon reduction of miR-27b is blocked by simultaneous inhibition of
PPARγ (Figure 5a), suggesting that the effects of miR-27b are mediated through PPARγ. In
accord with these observations, tumors harvested from the mice either treated with GW9662
or with miR-27b show significantly lower NF-κB activity and reduced IL-6 mRNA
expression relative to control groups (Figure 5c). Lastly, neuroblastoma cell growth is
inhibited upon treatment with an NF-κB inhibitor (BAY-117082; Figure 5d) at
concentrations that do not affect the growth of non-transformed cells (Supplementary Figure
2). Thus, miR-27b and PPARγ regulate the inflammatory response in neuroblastoma cells.
DISCUSSION
Our study identifies a molecular pathway important for growth and tumor progression of
neuroblastomas cells (Figure 6). Specifically, miR-27b functions as a tumor suppressor by
directly inhibiting the expression of PPARγ. Inhibition of PPARγ by miR-27b, si-RNA, or
a pharmacological antagonist reduces expression of NHE1 (presumably by direct binding to
the promoter region) and the inflammatory response (by an unknown mechanism).
Furthermore, inhibition of PPARγ results in reduced cell growth in vitro and tumor growth
in mouse xenografts, indicating that PPARγ functions as a tumor-promoting factor in
neuroblastomas. In accord with this tumor-promoting function, PPARγ stimulates NHE1
expression and inflammation, both of which are linked to tumor progression in multiple cell
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ttypes. Our results do not exclude additional cancer-related functions for miR-27b or for
PPARγ in neuroblastoma, and indeed these are likely.
Our study also provides new insights on how a transcription factor can act either as an
oncogene or tumor suppressor depending on the cell type. PPARγ activates NHE1
expression in neuroblastomas, but it inhibits NHE1 expression in breast cancer cells, and
this discordant regulation of NHE1, an oncogenic factor, is linked to tumor suppression in
breast cells and tumor promotion in neuroblastomas (Figure 6). There are many examples in
which a DNA-binding transcription factor can directly activate or repress genes in a given
cell type, or directly activate or repress a given gene in different cell types. We therefore
suggest that PPARγ has oncogenic or tumor suppressor functions in different cell types by
virtue of cell-type-specific regulation of NHE1 and perhaps other target genes.
MATERIALS AND METHODS
Cell lines
The neuroblastoma cell line SK-N-AS (American Type Culture Collection) was maintained
in DMEM media (Invitrogen) containing 10% fetal bovine serum (Atlanta Biologicals), and
penicillin/streptomycin (Invitrogen) at 37°C with 5% CO2. The breast epithelial cell line
MCF-10A cells containing the ER-Src fusion protein was grown in DMEM/F12 medium
supplemented with 5% donor HS, 20 ng/ml epidermal growth factor (EGF), 10 mg/ml
insulin, 100 mg/ml hydrocortisone, 1 ng/ml cholera toxin, and 50 units/ml pen/strep, with
the addition of puromycin (Hirsch et al., 2009; Iliopoulos et al., 2009). To induce
transformation, the Src oncogene was activated by the addition of 1 mM tamoxifen (Sigma,
St. Louis) for 36 hours.
Luciferase assays
The firefly luciferase reporter plasmids contained the entire wild-type 3′UTR of PPARγ
(Genecopeia Inc.) or a mutated derivative deleted for the 8 bp seed sequence deleted
generated by inverse-PCR (Supplementary Table 1). The Renilla plasmids (0.8 μg) were co-
transfected into SK-N-AS cells either with 33 nM of as-miR-27b (AM10750, Ambion),
miR-27b (C-300589-05, Dharmacon) or non-targeting control (NC) (PM11440, Ambion)
using Lipofectamine™ 2000 (Invitrogen) to the cells. The PPARγ luciferase activity of the
luciferase vector construct only (UT) was normalized to one and the other transfection
combinations were compared with UT. Cells were harvested 48 h after transfection and
assayed using the Dual Luciferase Reporter Assay System (Promega).
RNA analysis
RNA was purified by the Trizol method (Invitrogen, Carlsbad, CA), treated with RNase-free
DNase (Ambion), and reverse transcribed with using SuperScript III RT (Invitrogen) to
generate cDNA. RNA levels were determined by SYBR Green-based real-time PCR of the
cDNA, with the level of β-actin used as a loading control. Each sample was run in triplicate,
and the data represent the mean ± SD of three independent experiments. PCR primers used
for these analyses are shown in Supplementary Table 1.
Western blotting
Total protein (50 μg) from neuroblastoma cells was isolated by standard methods in RIPA
buffer (25 mM Tris.HCl pH7.6, 150 mM NaCl, 1% NP-40, 1% sodium, deoxycholate, 0.1%
SDS), electrophoretically separated, and transferred to nitrocellulose filters. The filters were
incubated overnight at 4°C with anti-PPARγ (1:200; ab27649, Abcam Inc.) and anti-α-
tubulin (1:3000; Clone DM1A, Sigma). The density of the bands was quantified and
normalized by the loading control, γ-tubulin.
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tGenetic and pharmacological analysis of cell growth
For genetic analysis, SK-N-AS cells seeded in 6- or 12-well plates were transfected with 100
nM miRNAs, antisense (as)-miRNAs or siRNAs using the siPORT NeoFX transfection
agent (Ambion) and incubated for 24 hours. The number of viable cells was measured at
various times after this initial incubation period. For pharmacological analysis, cells were
seeded in 24-well plates for an initial 20 hour incubation period, after which time they were
treated with medium containing 15 μM GW9662 (PPARγ antagonist; Cayman Chemical), a
5 μM BAY-11-72 (NF-kB inhibitor; Sigma), or DMSO (vehicle). Medium containing these
inhibitors was changed every 24 hours.
Soft agar colony and invasion assays
The soft agar colony and MATRIGEL invasion assays for MCF-10A-ER-Src cells were
performed as described previously (Iliopoulos et al., 2009; Hirsch et al., 2010).
Xenograft experiments
SK-N-AS cells (5 × 106) were injected into the right flank of nu/nu mice (Charles River
Laboratories), all of which developed tumors in 10 days with size of ~60 mm3. The mice
were randomly distributed into groups (typically 4 mice per group) and treated with
miR-27b (100 nM), miRNA negative control (miR-NC; 100 nM), GW9662 (2.5 mg/kg), or
DMSO (0.1 ml/10 g body weight). All treatments were given by intraperitoneal (i.p)
injection every five days starting on day 10 to day 25 for 4 cycles. Tumor volumes were
monitored every five days. Tumors were harvested on day 35 for mRNA analysis of PPARγ
and NHE1 and for measurements of NF-kB activity (ActivELISA kit IMK-503 from
Imgenex). All mouse experiments were performed according to the Institutional Animal
Care and Use Committee procedures and guidelines of Tufts University.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. miR-27b targets the 3′UTR of PPARγ
(a) Sequence complementarity (vertical lines showing the seed sequence between positions
82–88) between miR-27b and the PPARγ. Luciferase activity of reporters containing the
wild-type or 8-bp deleted 3′UTR of PPARγ 24h after transfection with miR-27b, antisense
(as) against miR-27b or miR negative control or non-transfected cells (UT). (b) PPARγ
mRNA levels in SK-N-AS cells transfected with as-miR-27a (gray bar) or as-miR-27b
(white bar). (c) Western blot showing PPARγ protein levels in cells transfected with the
indicated RNAs; levels of GAPDH serve as a loading control. (d) PPARγ mRNA levels in
mouse xenografts (SK-N-AS cells) that are or are not injected with miR-27b.
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tFigure 2. miR-27b through PPARγaffecting the cell growth in neuroblastoma cancerin vitro and
in vivo
(a) Relative umber of viable SK-N-AS cells that were transfected with the indicated RNAs
for 24 hours and then allowed to grow for an additional 24 hours. UT indictes untreated (i.e.
no siRNA). (b) Tumor growth (mean ± SD) of mouse xenografts containing neuroblastoma
(SK-N-AS) cells after intraperitoneal treatment with miR-27b, as-miR-27b or control
miRNA on the indicated number of days after the initial injection of cancer cells. (c)
miR-27b RNA levels in neuroblastoma and adjacent non-cancer tissues from 9 patients, with
each line representing an individual patient. (d) Growth of SK-N-AS cells in the presence or
absence of GW9962 for the indicated number of days. (e) Tumor growth (mean ± SD) of
mouse xenografts containing neuroblastoma (SK-N-AS) cells after intraperitoneal treatment
with GW9662 (or no treatment) on the indicated number of days after the initial injection of
cancer cells.
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tFigure 3. PPARγ functions as a tumor suppressor in a isogenic model of transformation in
breast cells
(a) Colony formation in soft agar of the ER-Src cells that were or were not treated with
tamoxifen (TAM) and/or transfected with miR-27b, siRNA against PPARγ, or control
siRNA and miRNA. (b) Invasive growth (invading cell/field after wounding) of the cells
described in panel a. (c) Tumor growth (mean ± SD) of mouse xenografts containing
transformed ER-Src cells after intraperitoneal treatment with siRNA against PPARγ or
control siRNA on the indicated number of days after the initial injection of cancer cells. (d)
PPARγ RNA levels in the indicated breast cancer cell lines treated with miR-27b, as-
miR-27b, or control miRNA. (e) Invasive growth in the indicated breast cancer cell lines
treated with miR-27b, as-miR-27b, or control miRNA.
Lee et al. Page 12








































































tFigure 4. PPARγ promotes cell-growth in vitro and in vivo
(a) NHE1 RNA levels in SK-N-AS cells that were or were not treated with as-miR-27b
RNA or control miRNA. (b) NHE1 RNA levels in mouse xenografts (SK-N-AS cells) that
are or are not injected with miR-27b. (c) PPARγ and NHE1 RNA levels in SK-N-AS cells
treated with siRNA against PPARγ or control siRNA. (d) PPARγ and NHE1 RNA levels in
SK-N-AS cells that were or were not treated with GW9662. (e) PPARγ and NHE1 RNA
levels in mouse xenografts containing SK-N-AS cells that were or were not treated with
GW9662.
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tFigure 5. miR-27b through PPARγ regulates the NF-κB pathway in neuroblastoma cells and
tumors
(a) RNA levels of the indicated inflammatory genes in SK-N-AS cells treated with the
indicated RNAs. (b) RNA levels of the indicated inflammatory genes in SK-N-AS cells that
were or were not treated with GW9662. (c) NF-κB activity or IL6 RNA levels in tumors
from mouse xenografts (SK-N-AS cells) that are treated with miR-27b or control miRNA or
GW9662. (d) Number of SK-N-AS cells after treatment with the indicated inhibitors.
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In neuroblastoma, miR-27b inhibits PPARγ, which functions as an oncogene that activates
downstream targets NHE1 and NF-κβ in tumor development. In breast cancer cells, PPARγ
functions as a tumor suppressor that inhibits NHE1 expression.
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